A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks.
- Resource Type
- Article
- Source
JAIDS: Journal of Acquired Immune Deficiency Syndromes . 4/15/2009, Vol. 50 Issue 5, p474-481. 8p. 3 Charts, 2 Graphs.- Subject
- *
DOSE-effect relationship in pharmacology
*DRUG efficacy
*ANTIRETROVIRAL agents
*VIRUS research
*CLINICAL medicine - Language
- ISSN
- 1525-4135